Marc Tessier-Lavigne, Xaira Therapeutics CEO
June 17, 2025 12:00 PM EDT
AI

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Andrew Dunn

Senior Biopharma Correspondent

Last spring, Xaira Ther­a­peu­tics launched with over a bil­lion dol­lars, a star-stud­ded team and big dreams to re­make R&D with AI. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

Lyell’s lym­phoma da­ta for re­cent­ly ac­quired CAR-T re­ceive luke­warm re­cep­tion on Wall Street

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

Prothena moves for­ward with lay­offs; Aldeyra re­sub­mits dry eye drug to FDA

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times